Correction of the high blood viscosity syndrome by a mixture of Diquertin and Ascorbic Acid in vitro and in vivo.
Diquertin was shown to diminish blood viscosity, to decrease the aggregation of erythrocytes, and to increase their deformability using a model of the high blood viscosity syndrome in vitro. A mixture of Diquertin with Ascorbic Acid was more effective in improving rheological indicators of blood, then either Diquertin or Tanakan. On a model of chronic brain ischemia, which is accompanied by significant deterioration of the rheological properties of blood, it was shown that a therapy with a mixture of Diquertin and Ascorbic Acid decreases the expression of the high blood viscosity syndrome.